Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

not_yet_recruiting2100%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_3

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

NCT07013123
not_yet_recruiting

Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis

NCT06741800

Clinical Trials (2)

Showing 2 of 2 trials
NCT07013123Phase 3

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

Not Yet Recruiting
NCT06741800

Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2